Physician profile
George E Artzberger
NPI 1578521290
$6,711.26
in general payments reported to CMS, 2019-2025
49 companies · $845 in 2025
The $845 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $1,012 · 2021: $1,424 · 2022: $1,099 · 2023: $892 · 2024: $847 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,164.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $731.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $628.95 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $366.87 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $322.16 | 2019-2025 | |
| Abbvie INC. | $303.12 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $291.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.42 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $214.53 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.22 | 2020-2025 | Xifaxan |
| Mallinckrodt Enterprises LLC | $185.76 | 2019 | |
| Astellas Pharma US INC | $184.26 | 2021-2023 | Myrbetriq |
| Dexcom, INC. | $144.61 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $138.95 | 2020-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $99.64 | 2022-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Artzberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.